Investment
Features
FeesSafety
Academy
More
Pluang+

Compare F.N.B. Corporation Common Stock (FNB) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance

F.N.B. Corporation Common StockTrade
Vaxcyte Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

F.N.B. Corporation Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? F.N.B. Corporation Common Stock trades at $16.91 (market cap $6.07B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is the larger of the two by market cap, and F.N.B. Corporation Common Stock pays a 3.05% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.

FNBPCVX
Market Cap
$6.07B$10.51B
Volume
5,600,6092,644,694
Sector
FinancialsHealth
52-Week High
$19.49$73.82
52-Week Low
$14.65$40.32
Typical Hold Time
0 Days0 Days
Enterprise Value
$10.61B$9.14B
Dividend Yield
3.05%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

F.N.B. Corporation Common Stock

FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.

The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.

Vaxcyte Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FNB
100% Buy0% Sell
Avg holding period · 0 Days
PCVX
100% Buy0% Sell
Avg holding period · 0 Days

About F.N.B. Corporation Common Stock

F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.

Read more on FNB →

About Vaxcyte Inc. Common Stock

Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.

Read more on PCVX →